Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Gan To Kagaku Ryoho ; 49(1): 97-99, 2022 Jan.
Artículo en Japonés | MEDLINE | ID: mdl-35046374

RESUMEN

A 70-year-old woman underwent a partial mastectomy with preoperative diagnosis of phyllodes tumor. Histopathological examination of the resected specimen revealed noninvasive ductal carcinoma of up to 20 mm in the phyllodes tumor. We note the possibility of a situation in which a phyllodes tumor is accompanied by cancer, and detailed pathological examination is necessary.


Asunto(s)
Neoplasias de la Mama , Carcinoma Ductal de Mama , Tumor Filoide , Anciano , Neoplasias de la Mama/cirugía , Carcinoma Ductal de Mama/cirugía , Femenino , Humanos , Mastectomía , Mastectomía Segmentaria , Tumor Filoide/cirugía
2.
Breast Cancer ; 27(5): 954-962, 2020 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-32301097

RESUMEN

BACKGROUND: Chemotherapy-induced taste and smell alterations in cancer patients are associated with multiple adverse effects, namely, malnutrition, weight loss, and a diminished quality of life. The aim of this prospective study was to identify the incidence of taste alterations following epirubicin and cyclophosphamide (EC) chemotherapy in patients with breast cancer without previous history of cancer or chemotherapy. METHODS: Forty-one patients undergoing EC chemotherapy for breast cancer at Tokai University Hospital were included. A subjective (questionnaire) and an objective (filter paper disk method) assessment for 5 basic tastes were administered on day 4 post-chemotherapy and immediately before the subsequent cycle of chemotherapy for each cycle, in addition to an olfactory evaluation and oral examination. The correlation between subjective and objective taste alterations and factors influencing these alterations were analyzed by statistical means. RESULTS: The mean incidence of subjective taste alteration on the 4th day after chemotherapy was 53%. In each of the 4 cycles, taste alterations decreased to about 9.0% immediately before the next cycle. A significant correlation between subjective and objective assessments was seen only for salty taste, suggesting important differences in subjective versus objective assessment outcomes. A multivariate analysis indicated that age and body surface area influenced taste alterations. CONCLUSIONS: EC chemotherapy induced taste alterations in more than 50% of patients, which decreased to less than 10% immediately before the next chemotherapy cycle. A combination of objective and subjective assessments is essential to evaluate taste alterations induced by EC chemotherapy. These could be used in routine clinical practice.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/tratamiento farmacológico , Trastornos del Olfato/epidemiología , Trastornos del Gusto/epidemiología , Umbral Gustativo/efectos de los fármacos , Adulto , Anciano , Ciclofosfamida/efectos adversos , Epirrubicina/efectos adversos , Femenino , Humanos , Incidencia , Persona de Mediana Edad , Trastornos del Olfato/inducido químicamente , Trastornos del Olfato/diagnóstico , Estudios Prospectivos , Calidad de Vida , Autoinforme/estadística & datos numéricos , Olfato/efectos de los fármacos , Trastornos del Gusto/inducido químicamente , Trastornos del Gusto/diagnóstico
3.
Int J Clin Oncol ; 23(6): 1038-1045, 2018 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-30047071

RESUMEN

BACKGROUND: There are few quality of life (QOL) studies that have focused on the experiences of oral cancer patients. Therefore, the present study aimed to investigate how the QOL for patients with oral cancer changed perioperatively. METHODS: Eighty-three participants undergoing radical therapy completed assessments of QOL at pre-treatment, treatment completion, and 1-, 3-, and 6-months post-treatment. The Japanese version of the FACT-H&N, comprising the subscales of "physical well-being (PWB)," "social/family well-being (SWB)," "emotional well-being (EWB)," "functional well-being (FWB)," and "additional head- and neck-specific concerns(HN)" was used to assess QOL. There were two study groups: those who required reconstructive surgery (r+, 31 patients) and those who did not (r-, 52 patients). RESULTS: The FACT-H&N, PWB, FWB, and HN, were lowest at treatment completion due to declines; then, it showed significant improvement over time (p < 0.05). SWB was the highest at the completion of treatment, and thereafter decreased significantly until 3 months after treatment (p < 0.05). EWB was the lowest before treatment but improved over time (p < 0.01). HN was significantly lower at 6 months after treatment than before treatment (p < 0.05). The QOL of the r+ group was significantly lower than that of the r- group (p < 0.01). CONCLUSIONS: The treatment-associated declines in subscale area may be compensated for by gains in other subscale areas. Psychological support is better introduced prior to cancer treatment. As it is often difficult to recover from declines in HN functioning subscale, strategies that promote compensation in other areas must be explored. Clinicians should become thoroughly familiar with how patients' QOL changes over time and provide holistic treatments that honor patients' autonomy.


Asunto(s)
Neoplasias de la Boca/cirugía , Periodo Perioperatorio , Calidad de Vida , Adulto , Anciano , Anciano de 80 o más Años , Femenino , Estado de Salud , Humanos , Estudios Longitudinales , Masculino , Persona de Mediana Edad , Neoplasias de la Boca/patología , Neoplasias de la Boca/psicología , Estudios Prospectivos , Encuestas y Cuestionarios , Resultado del Tratamiento , Adulto Joven
4.
Mol Clin Oncol ; 8(1): 68-72, 2018 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-29399347

RESUMEN

Lateral retropharyngeal lymph node (LRPLN) is located between the internal carotid artery and the prevertebral muscles. Metastasis to the LRPLN is frequent in nasopharyngeal cancer, but is rare in oral cancer. The prognosis of patients with oral cancer with LRPLN metastasis is usually poor. The present study reported a patient with LRPLN metastasis from squamous cell carcinoma of the upper gingiva, who survived for >7 years. Docetaxel, cisplatin and fluorouracil (TPF) therapy was performed as induction chemotherapy and it was planned to subsequently conduct chemoradiotherapy or surgery. As the tumor only exhibited a transient response to TPF, surgery was selected. Postoperatively, only radiotherapy was performed and a favorable outcome was achieved.

6.
Tokai J Exp Clin Med ; 42(1): 19-24, 2017 Apr 20.
Artículo en Inglés | MEDLINE | ID: mdl-28413867

RESUMEN

OBJECTIVE: The aim of this study was to assess the feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer. METHODS: Patients with high-risk pathological features were selected from patients with oral squamous cell carcinoma who underwent surgery at the Department of Oral and Maxillofacial Surgery, Tokai University Hospital. Patients were given adjuvant chemoradiotherapy with tri-weekly cisplatin (100 mg/m2) (66 Gy/33 Fr), and the treatment completion rate was examined. RESULTS: A total of 27 patients were enrolled between April 2011 and December 2012, including 19 males and 8 females. The median follow-up period was 36 months, and the protocol completion rate was 81.5%. Grade 3 or higher adverse events included leukopenia in 16 patients (59.3%), anemia in 7 patients (25.9%), mucositis in 2 patients (7.4%), increased creatinine in 1 patient (3.7%), nausea in 4 patients (14.8%), and anorexia in 12 patients (44.4%). The 3-year overall survival rate was 66.7%, relapse-free survival rate was 63.0%, and locoregional control rate was 77.8%. CONCLUSION: The feasibility and safety profile of concurrent chemoradiotherapy with cisplatin in Japanese patients with postoperative high-risk oral cancer were comparable to pivotal phase III trials.


Asunto(s)
Antineoplásicos/administración & dosificación , Carcinoma de Células Escamosas/terapia , Quimioradioterapia Adyuvante , Cisplatino/administración & dosificación , Neoplasias de la Boca/terapia , Adulto , Anciano , Pueblo Asiatico , Carcinoma de Células Escamosas/cirugía , Esquema de Medicación , Estudios de Factibilidad , Femenino , Humanos , Masculino , Persona de Mediana Edad , Neoplasias de la Boca/cirugía , Periodo Posoperatorio , Pronóstico , Dosificación Radioterapéutica , Riesgo , Seguridad
7.
Tokai J Exp Clin Med ; 41(3): 112-7, 2016 Sep 20.
Artículo en Inglés | MEDLINE | ID: mdl-27628601

RESUMEN

We investigated whether neck dissection should be performed to prevent T1-2N0M0 tongue cancer by using the Weiss and colleague's decision tree method. The results showed that preventive neck dissection should not be recommended for T1-2N0M0 tongue cancer. However, preventive neck dissection is a suitable approach when treating tongue cancer tumors with a thickness of ≥ 4 mm.


Asunto(s)
Carcinoma de Células Escamosas/cirugía , Procedimientos Quirúrgicos Electivos , Disección del Cuello , Neoplasias de la Lengua/cirugía , Anciano , Análisis de Varianza , Carcinoma de Células Escamosas/patología , Carcinoma de Células Escamosas/prevención & control , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estadificación de Neoplasias , Estudios Retrospectivos , Neoplasias de la Lengua/patología , Neoplasias de la Lengua/prevención & control
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...